Back to Library

Johnson & Johnson

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

Written by
Johnson & Johnson logoJohnson & Johnson
• Published August 8, 2025 • Updated August 8, 2025 Sponsored Content
FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

THE MOST PRESCRIBED

IL-23i in active PsA*

*Year-to-date TREMFYA® active PsA market share vs IL-23 inhibitors as of January 2024.

Give your patients the opportunity to emerge with:

Ankle and foot with pain icon
Ankle and foot with pain icon

Rapid joint improvement proven to last at 2 years*†‡

Rapid joint improvement at Week 24 (primary endpoint) with response as early as Week 4 and continued improvement at 2 years* (OLE NRI post hoc analysis)1-7

See the full details: joint efficacy

Extensive relief: More than just lasting skin clearance at 2 years†

Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA1-6

See the full details: additional data

Proven safety profile in psoriatic disease§

Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA1

See the full details: safety profile

HAQ-DI=Health Assessment Questionnaire-Disability Index; IL-23i=interleukin-23 inhibitor; MDA=Minimal Disease Activity; NRI=nonresponder imputation; OLE=open-label extension.

*The same patients may not have responded at each time point.

†Year 2 represents Week 100.

‡After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.

§Psoriatic disease is defined as moderate to severe plaque psoriasis and active PsA.

Woman in white shirt and in white room looking down at laptop
Woman in white shirt and in white room looking down at laptop

Robust|| coverage &
dedicated patient support

92% nationally preferred, first-line commercial coverage, no step edit required, including TNFi biosimilars7¶#

ONCE A PRESCRIBING DECISION HAS BEEN MADE

See access & support

The information provided does not imply comparable safety or efficacy between products and only represents access information. Humira is a registered trademark of AbbVie Inc. Please refer to each product’s prescribing information for indication(s), recommended dosing, and administration.

ǁRobust = >80% of commercially covered lives.

These percentages may not represent 100% of formulary lives due to data limitations.

#“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.

cp-440340v1

Have a discussion with a Janssen representative

Contact your local sales rep

Register for updates about TREMFYA®

Register to receive updates

References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 3. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Poster presented at: Innovations in Dermatology 2021; Virtual; March 16-20, 2021. 6. Data on file. Janssen Biotech, Inc. 7. Data provided by Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of October 2023.